𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Maintenance with low-dose cytarabine for acute myeloid leukemia in complete remission

✍ Scribed by E. Archimbaud; B. Anglaret; X. Thomas; J. Jaubert; C. Sebban; D. Guyotat; D. Fiere

Book ID
105280718
Publisher
Springer
Year
1992
Tongue
English
Weight
386 KB
Volume
65
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Low dose interleukin-2 following intensi
Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission
✍ Richard M. Stone; Daniel J. DeAngelo; Anna Janosova; Ilene Galinsky; Christine C πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 343 KB πŸ‘ 2 views

## Abstract The most important problem in the therapy of patients with acute myeloid leukemia (AML) is relapse after intensive therapy. We sought to determine if interleukin‐2 (low‐dose with intermittent boluses) administration could be feasibly administered after standard therapy to potentiate ant

Intensive timed sequential remission ind
Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia
✍ Loeb, David M. ;Bowers, Daniel C. ;Civin, Curt I. ;Friedman, Alan D. πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 91 KB

## Background: Timed sequential chemotherapy and high-dose cytarabine (cytosine arabinoside, ara-c; hdac) are both effective treatments for acute myeloid leukemia (aml). we review our institutional experience with timed sequential induction chemotherapy consisting of daunorubicin/ara-c/-thioguanine

Arsenic trioxide and low-dose cytarabine
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia
✍ Gail J. Roboz; Ellen K. Ritchie; Tania Curcio; Juliette Provenzano; Rebecca Carl πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 135 KB

## Abstract ## BACKGROUND. Acute myeloid leukemia (AML) carries a dismal prognosis in older patients. In this study, the authors evaluated the safety and efficacy of arsenic trioxide combined with low‐dose cytarabine in untreated patients aged β‰₯60 years with AML. ## METHODS. In a phase 1/2 desig

Low-dose adriamycin remission maintenanc
Low-dose adriamycin remission maintenance for advanced acute lymphoblastic leukemia: A southwest oncology group study
✍ Hvizdala, Eva ;Komp, Diane ;Ragab, Abdel ;Crist, William ;Chu, Jen-Yih πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 295 KB

## Abstract A low‐dose maintenance schedule of adriamycin was evaluated in children with advanced acute lymphoblastic leukemia. Thirty‐six evaluable patients who achieved two or more remissions were given adriamycin, 10 mg/m^2^/week, as a single maintenance agent. The median duration of second remi